Trials / Withdrawn
WithdrawnNCT04409483
Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Epicentre · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.
Detailed description
After being informed about the study and potential risks, all patients who meet all eligibility criteria and who give written informed consent will be randomized to receive standard care or standard care plus lopinavir/ritonavir (400mg/100mg twice daily for 14 days). Participants will receive daily visits from study staff for 15 days and be followed for a total of 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir-Ritonavir Drug Combination | 400mg/100mg taken orally twice daily for 14 days. |
| COMBINATION_PRODUCT | Standard Care | Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-06-01
- Last updated
- 2021-02-10
Source: ClinicalTrials.gov record NCT04409483. Inclusion in this directory is not an endorsement.